Welcome to our dedicated page for STANDARD BIOTOOLS news (Ticker: LAB), a resource for investors and traders seeking the latest updates and insights on STANDARD BIOTOOLS stock.
Standard BioTools Inc. reports developments in life-science research tools built around proprietary mass cytometry and microfluidics technologies. The company sells instruments, consumables and services for genomics, single-cell proteomics and spatial proteomics, including platforms such as Biomark X9, CyTOF XT and Hyperion systems used in research workflows.
Recurring news includes operating and financial results, capital-structure updates, shareholder voting and governance matters, portfolio actions following the completed sale of SomaLogic assets, and collaborations that expand imaging mass cytometry and multi-omic research applications. Company updates also describe translational and clinical research use cases in oncology, immunology and immunotherapy, with products positioned for research use rather than diagnostic procedures.
Standard BioTools (NASDAQ: LAB) has announced its upcoming first quarter 2025 financial results release and conference call schedule. The company will disclose its Q1 2025 results on Tuesday, May 6, 2025, after the market closes.
A conference call and webcast are scheduled for the same day at 4:30 p.m. ET. Investors can participate through the following dial-in numbers:
- US domestic: (888) 346-3970
- International: (412) 902-4297
The webcast will be accessible through the company's Investor Relations page and will be archived at investors.standardbio.com for future reference.
Standard BioTools (NASDAQ: LAB) has announced its participation in three major investor conferences in March 2025. The company will present at TD Cowen's 45th Annual Healthcare Conference on March 3rd at 3:10 p.m. ET, attend investor meetings at the 2025 Leerink Partners Global Healthcare Conference on March 12th, and present at KeyBanc's 5th Annual Healthcare Forum on March 19th at 4:30 p.m. ET.
All presentations will be available via webcast on the company's Investor Relations website, with recordings archived at investors.standardbio.com.
Standard BioTools (NASDAQ: LAB) reported its Q4 and full year 2024 financial results, with full-year pro forma combined revenue of $175.1 million. The company achieved significant operational improvements, including a 17% reduction in pro forma operating loss and 33% year-over-year improvement in adjusted EBITDA.
Key financial highlights include additional $10 million in operational cost reductions, totaling $90 million in synergies over 12 months, and a strong balance sheet with $295 million in cash and no material debt. The company expects to reach adjusted EBITDA positive in 2026.
Q4 2024 revenue was $46.7 million, down 9% year-over-year, with consumables revenue up 10%, instruments revenue down 25%, and services revenue down 16%. For fiscal year 2025, Standard BioTools projects revenue between $165-175 million, factoring in anticipated NIH funding pressures in Americas academic revenue.
Standard BioTools (NASDAQ: LAB) has announced its upcoming fourth quarter and full year 2024 earnings conference call, scheduled for February 26, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss financial results and operational progress.
Investors can join via phone using (888) 346-3970 for US domestic callers or (412) 902-4297 for international participants. A live webcast will be available on the company's Investor Relations page, with an archived version accessible afterward at investors.standardbio.com.
Standard BioTools (NASDAQ: LAB) announced preliminary, unaudited revenue results for Q4 and the full year 2024.
For Q4, the company expects revenue of approximately $46.5 million, contributing to a full-year revenue of around $174 million. This meets the top end of their revised guidance, adjusted in Q2 to account for industry-wide challenges.
CEO Michael Egholm highlighted significant progress in reducing operating expenses through the implementation of Standard BioTools Business Systems (SBS). He emphasized the need for continued discipline and improvement. Looking ahead to 2025, the company aims to achieve further efficiencies from integration, enhancing their R&D and shifting revenues towards high-margin offerings.
Egholm expressed optimism about the company's strategy and team, aiming for long-term value for shareholders and customers. The company will report detailed financial results for Q4 and the full year 2024 later this quarter, along with their 2025 outlook.
The preliminary results are subject to completion of annual audit procedures and internal reviews.
Standard BioTools (NASDAQ: LAB) announced that its SomaScan Platform was instrumental in a Nature Medicine study examining semaglutide's effects on obesity treatment. The research, conducted by Novo Nordisk, analyzed approximately 6,400 human proteins across nearly 2,000 participants from two phase 3 trials.
The study revealed significant changes in protein biomarkers linked to metabolic pathways, providing new insights into semaglutide's biological mechanisms and potential broader health benefits. The SomaScan Technology demonstrated unique advantages, including mechanistic insights into proteins and pathways, reliable results across studies, and the potential to accelerate clinical development through a validated 27-protein predictor that detected cardiovascular benefits in smaller, shorter studies.
Standard BioTools (NASDAQ: LAB) announced that its President and CEO, Michael Egholm, PhD, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The event will be held from January 13th to 16th at the Westin St. Francis Hotel in San Francisco, CA. Dr. Egholm’s presentation is scheduled for January 16th, 2024, at 9:45 a.m. PT. A live audio webcast of the presentation will be accessible via the Investor Relations page on the company’s website. An archived recording will also be available for later access on the same page.
Standard BioTools (Nasdaq: LAB) has appointed Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and former Chief Operating Officer of Standard BioTools, brings nearly 30 years of healthcare and life sciences industry experience. Previously, he served as President of Milliken's Healthcare Division and held leadership positions at Pall and Danaher Throughout his career, Kim has completed over 40 transactions in healthcare, medical technology, and life sciences sectors. Concurrent with Kim's appointment, Jonathan Mickelsen has been promoted to Vice President & Chief Accounting Officer.
Standard BioTools (NASDAQ: LAB) has announced its management team's participation in two major investor conferences in November 2024. President and CEO Michael Egholm, PhD, will deliver corporate presentations at the UBS Global Healthcare Conference on November 12 at 1:15 p.m. PT and at the Jefferies London Healthcare Conference on November 19 at 8:30 a.m. GMT. The presentations will be webcast live on the company's Investor Relations page, with recordings archived at investors.standardbio.com.
Standard BioTools (NASDAQ: LAB) reported Q3 2024 revenue of $45 million, down 5% year-over-year. The company achieved a 50% adjusted EBITDA improvement and 35% net loss improvement year-over-year. Key financial metrics include: consumables revenue up 13%, instruments revenue down 42%, and services revenue flat. The company maintains $368 million in cash and investments. Operating expenses decreased 18.5% to $55 million, while net loss improved to $26.9 million. The company has operationalized $80 million in merger synergies, expected to be fully realized in 2025, and reaffirmed FY2024 revenue guidance of $170-175 million.